Aurora Cannabis Inc's stock is on the rise, reflecting strong performance in international medical markets.
In the latest trading session, Aurora Cannabis Inc (ACB.TO) saw its stock price increase by 0.48%, closing at CA$4.15. This uptick follows a positive quarterly report that highlighted significant growth in medical cannabis sales, especially outside of Canada.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Aurora Cannabis Inc
ACB.TO
ACB.TO
Aurora Cannabis Inc
WealthAwesomeMarket cap
$237.24M
52W high
$9.33
52W low
$3.74
1W change
-5.62%
Beta
1.35
Analyst Price Targets
Based on analyst covering ACB
Wall Street analysts forecast ACB stock price to rise 51.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$5.84
+51.3% Upside
Current Price
C$3.86
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ACB's historical volatility
30-Day Vol
41.0%
Annualized
90-Day Vol
48.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.23
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.64 | C$3.16 – C$4.19 |
| 60 trading days | C$3.43 | C$2.81 – C$4.18 |
| 90 trading days | C$3.23 | C$2.53 – C$4.12 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Aurora's shift towards medical cannabis and international markets seems to be paying off, making it a stock to watch for those interested in growth within the cannabis sector.
CA$320.6 million in FY26 net revenue
Aurora Cannabis exceeded revenue expectations with a reported net revenue of CA$320.6 million for FY26, showcasing the effectiveness of its medical-first strategy.
Bull case
The company reported an 11% increase in net revenue for FY26, fueled by an 18% rise in medical cannabis sales. With 55% of its revenue coming from outside Canada, Aurora is well-positioned to take advantage of the growing global demand for medical cannabis.
Bear case
Despite the positive revenue growth, Aurora faces challenges, including a 30% cut in Canadian reimbursement pricing and a notable decline in consumer cannabis sales, which could affect future profitability.
Strong Quarterly Performance
Aurora Cannabis reported a net revenue of CA$320.6 million for FY26, marking an 11% increase year-over-year. This growth was largely driven by an 18% rise in medical cannabis sales, which now make up 91% of the company's total revenue. This strong performance highlights the success of Aurora's strategic pivot towards medical cannabis, particularly in international markets.
Focus on International Markets
With about 55% of its revenue generated outside Canada, Aurora is strategically positioned to leverage the expanding global medical cannabis market. The company’s recent acquisition of Safari Flower Company enhances its capabilities in Europe, addressing both capacity and sourcing risks while tapping into the growing demand in Germany and Poland.
Challenges Ahead
Despite the positive momentum, Aurora faces hurdles, including a projected 30% cut in Canadian reimbursement pricing for medical cannabis. Additionally, the company is intentionally winding down its consumer cannabis segment, which experienced a 55% decline in revenue year-over-year. These factors could pose risks to future profitability and market performance.
Advertisement
